Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to learn about the natural progression of DCM (dilated cardiomyopathy) caused by BAG3 gene mutations. DCM is a condition as the heart muscle is weakened and the heart becomes enlarged. This makes it hard for the heart to pump enough blood for the body. The study is seeking up to about 35 participants who have: - BAG3 mutation (change in the gene) that causes or is likely to cause dilated cardiomyopathy - NYHA (New York Heart Association) Class I-IV at screening (Stage B-D) - Left Ventricular Ejection Fraction less than or equal to 50% (meaning reduced heart function) All participants in this study will receive their usual treatment. The investigators will observe the natural progression of people who have BAG3 DCM. This will help the investigators better understand the disease and aid in future research. Participants will take part in this study for one year. During this time, participants will visit the site at least 4 times (about every 3 months). Participants will undergo study procedures and give information about their health. These procedures will include a physical exam, cardiac magnetic resonance imaging, echocardiography, ECG monitoring, activity monitoring, cardiopulmonary exercise testing, and blood tests. Participants will answer questions about health and quality of life. The study team will also call participants about 1 time over the phone.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05981092
Study type Observational
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Status Recruiting
Phase
Start date October 14, 2022
Completion date August 9, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03560167 - Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation N/A
Terminated NCT00624520 - Mental Stress Reduction in Defibrillator Patients Phase 3
Completed NCT00549861 - Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR N/A
Terminated NCT04222101 - Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy N/A
Not yet recruiting NCT02517814 - Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01391507 - Pilot Study of COR-1 in Heart Failure Phase 2
Completed NCT01181414 - Spanish Atrial Fibrillation And Resynchronization Study Phase 4
Not yet recruiting NCT06091475 - Therapy to Maintain Remission in Dilated Cardiomyopathy N/A
Recruiting NCT03340675 - Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy Phase 2
Not yet recruiting NCT06039072 - Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function
Recruiting NCT03910725 - Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death
Terminated NCT01478087 - Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM) N/A
Recruiting NCT00221780 - Role of Left Ventricular Pacing Site N/A
Terminated NCT02958098 - My Research Legacy Pilot Study
Completed NCT00123071 - Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network N/A
Completed NCT00284713 - Progenitor Cell Therapy in Dilative Cardiomyopathy Phase 1/Phase 2
Completed NCT01260402 - Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure. N/A
Completed NCT04192214 - The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor Phase 2
Recruiting NCT03040947 - MRI Sequence and Imaging Protocol Development